Spero Therapeutics (NASDAQ:SPRO – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Volatility & Risk
Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500.
Institutional and Insider Ownership
25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Jaguar Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spero Therapeutics | 0 | 3 | 1 | 0 | 2.25 |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
Spero Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 387.80%. Given Spero Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Spero Therapeutics is more favorable than Jaguar Animal Health.
Earnings & Valuation
This table compares Spero Therapeutics and Jaguar Animal Health”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spero Therapeutics | $66.80 million | 1.07 | $8.57 million | $0.11 | 11.18 |
| Jaguar Animal Health | $27.79 million | 0.10 | -$53.43 million | ($3,731.33) | -0.00 |
Spero Therapeutics has higher revenue and earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Spero Therapeutics and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spero Therapeutics | 24.90% | 16.17% | 12.57% |
| Jaguar Animal Health | -187.88% | N/A | -131.45% |
Summary
Spero Therapeutics beats Jaguar Animal Health on 14 of the 14 factors compared between the two stocks.
About Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
